ResearchWhat the human studies measured, and what remains unknown.
CJC-1295 findings set down carefully. No practice runs here.


A closer look at a long-acting peptide, the findings in people, and the questions those findings leave open.
Explore the researchCJC-1295 was developed to stimulate growth hormone release. The long-acting version attaches to albumin, a protein in blood, which helps it remain in circulation. That longer exposure is the central finding behind its name. It is also why the exact form matters.
This guide follows the human research, then separates measured hormone changes from claims about everyday health. CJC-1295 has no FDA-approved medical use. The early studies leave substantial questions about benefits and long-term safety.
ResearchWhat the human studies measured, and what remains unknown.
EffectsHormone responses, proposed benefits, and safety concerns.
Dosing as studiedResearch amounts in context, without a personal regimen.
QuestionsThe distinctions behind the names, approval, and sport rules.

Small studies in healthy adults measured hormone changes, drug persistence, and short-term tolerability. A separate report examined hormone pulses.
Explore the study findings
These findings do not establish better sleep, less fat, or faster recovery. A changed hormone signal is a narrower outcome than improved health.
Read about effectsGrowth hormone-releasing hormone, or GHRH, normally signals the pituitary gland to release growth hormone. CJC-1295 is a synthetic version designed to act on that signaling system. Growth hormone then influences insulin-like growth factor 1, usually shortened to IGF-1.
The DAC addition lets the peptide bind albumin. In early research in healthy adults, this form produced hormone changes lasting several days. A result for that long-acting form cannot simply be applied to a product described as no-DAC.
Understand the DAC formThe form, the participants, the outcome, and the observation period all matter. A study in healthy adults answers a different question from a trial in people with a diagnosed condition. A hormone measurement answers a different question from a change in symptoms.
FDA's assessment of CJC-1295 brings those limits together with concerns about immune reactions and other adverse effects. Small studies cannot settle risks that may appear after prolonged exposure.

DAC and no-DAC are different ingredients.
Healthy volunteers do not represent every patient.
A hormone change is not a symptom improvement.
Short follow-up leaves long-term questions.
Use the research page for the study record, the effects page for benefits and harms, and the dosage page for what researchers administered. The questions page covers names, approval, and sport. Each keeps the difference between a measured response and a useful treatment visible.